HCV2021 Program

• Tuesday, July 6
• Wednesday, July 7
• Thursday, July 8
• Friday, July 9
• Download

Tuesday, July 6, 2021

• 10:00 10:15

  Welcome Address

  Naglaa Shoukry

• 10:15 10:45

  Plenary Lecture 1: Challenges of HCV Elimination

  Jordan Feld University of Toronto, Toronto, ON, Canada

• 10:45 12:45

  Session 1: Liver Inflammation, Viral Pathogenesis and Carcinogenesis

  Co-Chairs: Robert Thimme & Meital Gal-Tanamy
  
  10:45 - 11:15 | Plenary Lecture 2: Combination Approaches for the Treatment of NASH and Fibrosis
                             James Trevaskis - Gilead, Foster City, CA, USA
  
  11:15 - 11:45 | Keynote Lecture 1: Mapping the Human Liver using Single Cell RNAseq
                             Sonya MacParland - University of Toronto, Toronto, ON, Canada
  
  11:45 - 12:00 | BREAK
  
  12:00 - 12:45 | Oral Presentations selected from Abstracts  

  12:00 - 12:15 | Hepatitis C Virus Infection Restricts Human LINE-1 Retrotransposition in Hepatoma Cells
                             Anja Schoebel, Philipps University of Marburg, Germany

  12:15 - 12:30 | HCV NS3/4A protease cleaves SPG20 for formation of large lipid droplets
                             Chieko Matsui, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Japan

  12:30 - 12:45 | Contribution of the Cellular Lipid Kinase PI4KA to HCV-induced Liver Pathogenesis
                             Cong Si Tran, Heidelberg University, Germany

• 12:45 13:15

  Break

• 13:15 15:30

  Session 2: Tools for HCV Elimination: Diagnostics, Sequencing and Beyond

  Co-chairs: Jens Bukh & Emma Thomson
  
  13:15 - 13:45 | Plenary Lecture 3: Advances in HCV Diagnostics and Point of Care Testing
                             Jean-Michel Pawlotsky - National Reference Center for Viral Hepatitis B, C and Delta; Head, Department of Virology, Hôpital, Créteil, France
  

  13:45 - 14:15 | Keynote Lecture 2: How Realtime Data can Drive HCV Prevention, Care and Treatment: Lessons Learned from Fighting COVID-19
                             Mel Krajden - BC Centre for Disease Control, Vancouver, BC, Canada
  

  14:15 - 14:45 | Keynote Lecture 3: Tracking HCV Transmission using Next Generation Sequencing
                             Rowena Bull - University of New South Wales, Sydney, Australia
  

  14:45 - 15:30 | Oral Presentations selected from Abstracts  

  14:45 - 15:00 | Universal vs risk-based screening for prenatal Hepatitis C (HCV): a six-month comparison in Alberta, Canada
                             Alexa Thompson, University of Alberta, Canada

  15:00 - 15:15 | HCV diversity and treatment outcomes following direct-acting antiviral (DAA) therapy in Benin
                             Lucrèce Ahovègbé, Mbarara University of Science and Technology, Uganda

• 15:30 15:45

  Break

• 15:45 16:45

  Session 3: SARS‑CoV2 / HCV Interaction

  Co-chairs: Volker Lohmann & Joyce Wilson
  
  15:45 - 16:15 | Plenary Lecture: Broad spectrum antivirals for Coronavirus infections
                             Daria Hazuda - Vice-President, Infectious Disease and Vaccines, New York, USA
  

  16:15 - 16:45 | Oral Presentations selected from Abstracts  

  16:15 - 16:30 | SARS-CoV-2 entry is enhanced in HCV pre-infected hepatocytes leading to HCV-SARS-CoV2 co-infection state
                             Tom Domovitz, Bar Ilan University, Israel

  16:30 - 16:45 | Nucleoside-modified mRNA Lipid Nanoparticle Vaccine for HCV
                             Erin K Reagan, University of Pennsylvania, United States

• 16:45 17:00

  Break

• 17:00 18:00

  Nobel Prize Celebration

  Co-chairs: Lorne Tyrrell & Naglaa Shoukry
  
  Harvey Alter
  Michael Houghton
  Charles Rice

• 18:00 18:45

  Networking

• 18:45 19:00

  Day One Close